2012

Analysis of Survival of the Patients with Brain Metastases from Lung Cancer according to Treatment Modalities and Prognostic Indexes

OBJECTIVEThis study aimed to retrospectively evaluate overall survival (OS) of the patients with brain metastases(BM) from lung cancer who had been treated with whole-brain radiotherapy (WBRT) and gamma knife(GK) according to prognostic factors and prognostic score indexes.METHODSNinety-five patients with brain metastases from lung cancer were retrospectively evaluated using age, sex,lung cancer histological type, extracranial metastases, primary tumor control, number of brain metastases,total brain metastases volume, brain metastasectomy, chemotherapy, EGFR mutation, EGFR-TKI therapy,Karnofsky Performance Status (KPS), Recursive Partitioning Analysis (RPA) Class, Basic Score for BrainMetastases (BS-BM), Graded Prognostic Assessment Index (DS-GPA) and Modified Lung-Specific between 2015 and 2018. Univariate analysis of OS was performed using the Kaplan–Meier method supplemented by the log-rank test. We also applied multivariate survival analysis using the Cox Regression Model.RESULTSThe median OS for all patients with brain metastases from lung cancer was six months± SE: 0.807(range: 1–42 months; 95% CI: 4.419–7.581) and one-year overall survival rate was 25.3%. The median OS was four months, four months, 12 months in the WBRT arm, the GK arm and the combinedWBRT-GK arm, respectively (p=0.004). In multivariate analysis, treatment with WBRT–GK (p=0.030),brain metastasectomy (p=0.019), controlled primary tumor (p=0.004), chemotherapy (p=0.001) weresignificantly correlated with overall survival. BS-BM (p=0.033) was closely related to overall survivalcompared to other prognostic score indexes on the multivariate analysis.CONCLUSIONThe patients with BM benefited from WBRT and GK combined therapy. BS-BM for the survival of patients with BM from lung cancer is the most appropriate prognostic index.

PDF

___

1. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery and survival. Cancer 1996;78(8):1781−8.
2. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD. Stereotactic radio-surgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys 2006;64(3):898−903.
3. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2012;14(1):48−54.
4. Bradley KA, Mehta MP. Management of brain metastases. Semin Oncol 2004;31(5):693−701.
5. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363(9422):1665−72.
6. Patchell RA. The management of brain metastases. Cancer Treat Rev 2003;29(6):533−40.
7. Kocher M, Wittig A, Piroth MD, Treuer H, Seegenschmiedt H, Ruge M, et al. Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 2014;190(6):521−32.
8. Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2005;63(1):37−46.
9. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010;77(3):655−61.
10.Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29(2):134−41.
11.Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009;10(11):1037−44.
12.Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012;(4):CD003869.
13.Rades D, Janssen S, Bajrovic A, Khoa MT, Veninga T, Schild SE. A matched-pair analysis comparing wholebrain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases. Radiat Oncol 2017;12(1):69.
14.Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37(4):745−51.
15.Lorenzoni J, Devriendt D, Massager N, David P, Ruíz S, Vanderlinden B, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 2004;60(1):218−24.
16.Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008;70(2):510−4.
17.Marcus LP, Marshall D, Hirshman BR, McCutcheon BA, Gonda DD, Koiso T, et al. Cumulative Intracranial Tumor Volume (CITV) Enhances the Prognostic Value of the Lung-Specific Graded Prognostic Assessment (GPA) Model. Neurosurgery 2016;79(2):246−52.
18.Rades D, Janssen S, Dziggel L, Blanck O, Bajrovic A, Veninga T, et al. A matched-pair study comparing whole brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases. BMC Cancer 2017;17:30.
19.Yomo S, Hayashi M. The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brain radiotherapy for brain metastases. J Neurooncol 2013;113(3):459−65.
20.Soon YY, Tham IW, Lim KH, Koh WY, Lu JJ. Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev 2014;(3):CD009454.
21.Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457−81.
22.Wegner RE, Olson AC, Kondziolka D, Niranjan A, Lundsford LD, Flickinger JC. Stereotactic radiosurgery for patients with brain metastases from small cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81(3):e21−7.
23.Kevin S, Loeffler JS. The changing landscape of wholebrain radiation therapy invited commentary. JAMA Oncol 2015;1(4):464−5.
24.Bowden G, Kano H, Caparosa E, Park SH, Niranjan A, Flickinger J, et al. Gamma knife radiosurgery for the management of cerebral metastases from non-small cell lung cancer. J Neurosurg 2015;122(4):766−72.
25.Ebner DK, Gorovets D, Rava P, Cielo D, Kinsella TJ, DiPetrillo TA, et al. Patients with Long-Term Control of Systemic Disease Are a Favorable Prognostic Group for Treatment of Brain Metastases with Stereotactic Radiosurgery Alone. World Neurosurg 2017;98:266−72.
26.Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Chao ST, Barnett GH, et al. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer 2017;123(12):2283−93.
27.Likhacheva A, Pinnix CC, Parikh NR, Allen PK, McAleer MF, Chiu MS, et al. Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2013;85(3):656−61.
28.Baschnagel AM, Meyer KD, Chen PY, Krauss DJ, Olson RE, Pieper DR, et al. Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery. J Neurosurg 2013;119(5):1139−44.
29.Sengöz M, Kabalay IA, Tezcanlı E, Peker S, Pamir N. Treatment of brainstem metastases with gamma-knife radiosurgery. J Neurooncol 2013;113(1):33−8.
30.Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 2014;32(34):3810−6.
31.Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494−500.
32.Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33(6):583−90.
33.Harita S, Mizuta A, Kuyama S, Kikuchi T. Longterm survival following concurrent chemoradiotherapy in patients with non-small cell lung cancer with concomitant brain metastases only. Int J Clin Oncol 2005;10(1):63−8.
34.Kim KH, Lee J, Lee JI, Nam DH, Kong DS, Ahn YC, et al. Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? Lung Cancer 2010;68(2):258−63.
35.Kim DY, Lee KW, Yun T, Kim DW, Kim TY, Heo DS, et al. Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer. Oncol Rep 2005;14(1):207−11.
36.Galetta D, Gebbia V, Silvestris N, Ferraù F, Carrozza F, Cigolari S, et al. Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). Lung Cancer 2011;72(1):59−63.
37.Owen S, Souhami L. The management of brain metastases in non-small cell lung cancer. Front Oncol 2014;4:248.
38.Ji X, Zhuang Y, Yin X, Zhan Q, Zhou X, Liang X. Survival time following resection of intracranial metastases from NSCLC-development and validation of a novel nomogram. BMC Cancer 2017;17(1):774.
39.Gao HX, Huang SG, Du JF, Zhang XC, Jiang N, Kang WX, et al. Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery. Int J Biol Sci 2018;14(14):2065−72.
40.Harris KB, Corbett MR, Mascarenhas H, Lee KS, Arastu H, Leinweber C, et al. A Single-Institution Analysis of 126 Patients Treated with Stereotactic Radiosurgery for Brain Metastases. Front Oncol 2017;7:90.
41.Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47(4):1001−6.
42.Nieder C, Nestle U, Motaref B, Walter K, Niewald M, Schnabel K. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes? Int J Radiat Oncol Biol Phys 2000;46(2):297−302.
43.Villà S, Weber DC, Moretones C, Mañes A, Combescure C, Jové J, et al. Validation of the new Graded Prognostic Assessment scale for brain metastases: a multicenter prospective study. Radiat Oncol 2011;6:23.